Table III.
Study, year | Application | Examples | Refs. |
---|---|---|---|
Ruan et al, 2007 | Imaging | Tat-QDs | (55) |
Lei et al, 2008 | (56) | ||
Prantner et al, 2003 | Gd-DOTA-D-Tat | (57) | |
Polyakov et al, 2000 | Tat-(99m)Tc | (58) | |
Deshayes et al, 2010 | Anti-inflammation | CPP-PNA | (63) |
Tan et al, 2005 | (64) | ||
Tilley et al, 2007 | CPP-PMO | (65) | |
Davé et al, 2007 | CPP-NBD | (71) | |
Peterson et al, 2011 | Antp-NBD | (72) | |
Koshkaryev et al, 2013 | Tumor therapy | R8-DOPE-BLM | (76) |
Walker et al, 2012 | DOXO-ELP-CPP | (77) | |
Aroui et al, 2010 | Dox | (78) | |
Dubikovskaya et al, 2008 | Taxol | (79) | |
Lindgren et al, 2006 | Methotrexate | (80) | |
Eguchi and Dowdy, 2009 | Nucleic acid and Protein delivery | CPP-siRNA | (21) |
Muratovska and Eccles, 2004 | (82) | ||
Favaro et al, 2014 | T-Rp3 | (83) | |
Eto et al, 2009 | Viral delivery | CPP-Adv | (86) |